Kaur Bhupinder, Rosenblatt Russell, Sundaram Vinay
Internal Medicine Department, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Department of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA.
J Clin Transl Hepatol. 2022 Aug 28;10(4):718-725. doi: 10.14218/JCTH.2022.00024. Epub 2022 May 6.
Severe alcoholic hepatitis (sAH) is defined by a modified discriminant function ≥32 or model for end-stage liver disease (MELD) >20. Patients with sAH are in an immunocompromised state attributed to cirrhosis-related immunoparesis and corticosteroid use. Individuals with sAH often develop severe infections that adversely impact short-term prognosis. Currently, the corticosteroid prednisolone is the only treatment with proven efficacy in sAH; however, the combination of corticosteroid treatment and altered host defense in sAH has been thought to increase the risk of acquiring of bacterial, opportunistic fungal, and viral infections. Newer studies have shown that corticosteroids do not increase occurrence of infections in those with sAH; unfortunately, the lack of response to corticosteroids may instead predispose to infection development. Prompt and appropriate antibiotic treatment is therefore essential to improving patient outcomes. This review highlights common infections and risk factors in patients with sAH. Additionally, current diagnostic, therapeutic, and prophylactic strategies in these patients are discussed.
严重酒精性肝炎(sAH)的定义为改良判别函数≥32或终末期肝病模型(MELD)>20。sAH患者处于免疫功能低下状态,这归因于肝硬化相关的免疫麻痹和皮质类固醇的使用。sAH患者常发生严重感染,对短期预后产生不利影响。目前,皮质类固醇泼尼松龙是唯一已证实对sAH有效的治疗方法;然而,皮质类固醇治疗与sAH中宿主防御改变相结合被认为会增加获得细菌、机会性真菌和病毒感染的风险。最新研究表明,皮质类固醇不会增加sAH患者感染的发生率;不幸的是,对皮质类固醇缺乏反应反而可能易引发感染。因此,及时且适当的抗生素治疗对于改善患者预后至关重要。本综述重点介绍了sAH患者常见的感染及危险因素。此外,还讨论了这些患者目前的诊断、治疗和预防策略。